Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Janux Therapeutics Inc
(NQ:
JANX
)
44.90
-0.02 (-0.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Janux Therapeutics Inc
< Previous
1
2
Next >
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
August 07, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Announces Updates to Board of Directors
July 22, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 07, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 08, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
February 29, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Announces Proposed Public Offering of Common Stock
February 27, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors
February 26, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
February 20, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
January 08, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
November 07, 2023
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 08, 2023
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
July 17, 2023
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs
July 17, 2023
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
June 05, 2023
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 09, 2023
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences
April 24, 2023
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
April 20, 2023
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 10, 2023
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference
February 14, 2023
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors
December 27, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics to Present at Upcoming Investor Conferences in November
November 22, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
November 10, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer
October 12, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources
September 23, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics Appoints Winston Kung to Board of Directors
September 22, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September
August 31, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
August 09, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference
June 02, 2022
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer
May 31, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
May 10, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.